GlassScriptPhysician profile
Chad Michael Waggoner
NPI 1285686139
$2,955.64
in general payments reported to CMS, 2019-2025
20 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $91.70 · 2021: $199 · 2022: $554 · 2023: $457 · 2024: $426 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,248 · Travel and Lodging: $660 · Entertainment: $14.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,248.06 |
| Travel and Lodging | $659.96 |
| Entertainment | $14.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,117.29 | 2019-2025 | Total30, Precision 1, Precision7 |
| Johnson & Johnson Vision Care, INC. | $346.75 | 2020-2025 | Acuvue |
| Genentech USA, INC. | $242.61 | 2022-2023 | Vabysmo |
| Bausch & Lomb Americas INC. | $177.27 | 2022-2025 | Infuse, Blink Nutritears, Miebo |
| Abb Con-Cise Optical Group LLC | $172.54 | 2025 | Contact Lens, Spectacle Lenses |
| Regeneron Healthcare Solutions, INC. | $166.49 | 2022-2023 | Eylea |
| Abbvie INC. | $123.83 | 2022-2023 | Lumigan |
| Rxsight INC | $122.47 | 2022-2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Sight Sciences, INC. | $103.64 | 2021 | |
| Oyster Point Pharma, INC. | $93.30 | 2023-2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $73.30 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $39.48 | 2021-2023 | |
| Coopervision INC. | $33.40 | 2020-2021 | |
| Apellis Pharmaceuticals, INC. | $27.54 | 2023 | Syfovre |
| Kala Pharmaceuticals, INC. | $23.80 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $21.86 | 2023 | |
| Coherus Oncology, INC. | $21.85 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $20.24 | 2024 | Xdemvy |
| Optos, INC. | $14.33 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Horizon Therapeutics Plc | $13.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Waggoner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.